RxDoctor Payments Data

David Cunningham, MD

Family Medicine · Glens Falls, NYNPI 1659353027

Payments from drug & device makers

$1,643in general payments, 2019–2025

Across 72 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$887
  • AbbVie$219
  • AstraZeneca$150
  • Dexcom, Inc.$122
  • Lilly USA, LLC$72
  • Johnson & Johnson$47
  • plus $147 from 7 others

What the payments were for

  • Food & beverage$1,643100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,643 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$221,777
Medicare patients
483
Services billed
7,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NexviazymeAvalglucosidase Alfa-Ngpt13$1,364,592
EliquisApixaban91$97,565
JardianceEmpagliflozin70$66,100
XareltoRivaroxaban46$47,762
OzempicSemaglutide45$46,230
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$38,665
MounjaroTirzepatide30$30,519
ProliaDenosumab17$30,149
EntrestoSacubitril/Valsartan15$14,707
MyrbetriqMirabegron15$12,783
TrulicityDulaglutide13$12,377
TradjentaLinagliptin11$11,352
AmbienZolpidem Tartrate13$9,125
Repatha SyringeEvolocumab13$7,152
Praluent PenAlirocumab12$5,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$97,56591 claims
Johnson & JohnsonXarelto$47$47,76246 claims
Novo NordiskOzempic$30$46,23045 claims
Lilly USA, LLCMounjaro, Trulicity$72$42,89743 claims
GSKTrelegy Ellipta, Arnuity Ellipta$887$42,34971 claims
AmgenProlia$27$30,14917 claims
AbbVieSynthroid$219$4,55559 claims
AstraZenecaSymbicort$150$2,86814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Glens Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →